Weekly round up from Life Sciences Industry.
Continuing its deleveraging plan subsequent to its $62B Shire acquisition, Takeda Pharmaceutical Company Limited (NYSE:TAK) has agreed to sell a portfolio of certain non-core over-the-counter (OTC) and prescription products sold in Europe and two manufacturing sites, one in Poland and the other in Denmark, to Danish outfit Orifarm Group for ~$670M.
The portfolio generated ~$230M in sales in fiscal 2018.
Source: Seeking Alpha
Sign up for DistilINFO e-Newsletters.
Why HCAPHS is Archaic In Healthcare Today
Integra Tx Secures €4.5-million in Funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures
Roche extends deadline for Spark Therapeutics shareholders in $4.8B deal
Galen Partners Completes Acquisition of Evolve Treatment Centers, a Leading Provider of Adolescent Behavioral Health Services in California
Anixa Biosciences Reassures Shareholders It Has No Accounts at Silicon Valley Bank
6 Technology trends for 2018: Innovation focused on your digital journey
Ro Dips Into Skincare with New Prescription Dermatology Line
Seeman Holtz Property & Casualty Acquires Premier Medical Practice Group